Irradiation of Human Prostate Cancer Cells Increases Uptake of Antisense Oligodeoxynucleotide

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 4, 2007, Pages 1161-1168

  Anai, Satoshi ^a   Brown, Bob D ^c   Nakamura, Kogenta ^a   Goodison, Steve ^a,b   Hirao, Yoshihiko ^d   Rosser, Charles J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Genta Inc   (United States)

^d NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antisense; Cancer; Fluorescent; Oligodeoxynucleotide; Radiation

Indexed keywords

FLUORESCENT SIGNALS; OLIGODEOXYNUCLEOTIDE (ODN); PROSTATE CANCER; XENOGRAFT TUMORS;

CELL DEATH; CELL GROWTH; DNA; OLIGONUCLEOTIDES; RADIOTHERAPY; TISSUE;

ONCOLOGY;

ANTISENSE OLIGODEOXYNUCLEOTIDE; FLUORESCENT DYE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; COMPARATIVE STUDY; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); DRUG EFFICACY; DRUG UPTAKE; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; IRRADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE ENGINEERING; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FLUORESCENCE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; RADIATION DOSAGE; THIONUCLEOTIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 34447254041     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.03.058     Document Type: Article

References (24)

1. Galbraith W.M., Hobson W.C., Giclas P.C., et al. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4 (1994) 201-206
2. Crouch R.J. Ribonuclease H: Grom discovery to 3D structure. New Biol 2 (1990) 771-777
3. Chiang M.Y., Chan H., Zounes M.A., et al. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266 (1991) 18162-18171
4. Condon T.P., and Bennett C.F. Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells. J Biol Chem 271 (1996) 30398-30403
5. Delong R., Stephenson K., Loftus T., et al. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci 86 (1997) 762-764
6. Bongartz J.P., Aubertin A.M., Milhaud P.G., et al. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 22 (1994) 4681-4688
7. Anai S., Goodison S., Shiverick K., et al. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization in the human PC3 prostate tumor model. Mol Cancer Ther 6 (2007) 101-111
8. Zhou J.H., Rosser C.J., Tanaka M., et al. Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther 9 (2002) 681-686
9. Wick W., Furnari F.B., Naumann U., et al. PTEN gene transfer in human malignant glioma: Sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18 (1999) 3936-3943
10. Cowen D., Salem N., Ashoori F., et al. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin Cancer Res 6 (2000) 4402-4408
11. Anai S., Goodison S., Shiverick K., et al. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther 17 (2006) 975-984
12. Gleave M., Tolcher A., Miyake H., et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5 (1999) 2891-2898
13. Giles R.V., Spiller D.G., and Tidd D.M. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 5 (1995) 23-31
14. Monia B.P., Lesnik E.A., Gonzalez C., et al. Evaluation of 2″-modified oligonucleotides containing 2″-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268 (1993) 14514-14522
15. Agrawal S., Temsamani J., and Tang J.Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 88 (1991) 7595-7599
16. Agrawal S., Zhang X., Lu Z., et al. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50 (1995) 571-576
17. Cossum P.A., Truong L., Owens S.R., et al. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 269 (1994) 89-94
18. Crooke R.M., Graham M.J., Cooke M.E., et al. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 275 (1995) 462-473
19. Stein C.A., Tonkinson J.L., Zhang L.M., et al. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32 (1993) 4855-4861
20. Yip K.W., Mocanu J.D., Au P.Y., et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11 (2005) 8131-8144
21. Webb A., Cunningham D., Cotter F., et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349 (1997) 1137-1141
22. Tolcher A.W., Chi K., Kuhn J., et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 3854-3861
23. Tolcher A.W. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 28 (2001) S67-S70
24. Morris M.J., Tong W.P., Cordon-Cardo C., et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8 (2002) 679-683